Background Community-acquired pneumonia (CAP) causes considerable morbidity and
mortality in adults, particularly in the elderly. Methods Structured searches of PubMed were …

Background Diseases caused by Streptococcus pneumoniae (S. pneumoniae) continue to
cause substantial morbidity and mortality globally. Whilst pneumococcal polysaccharide …

Background Pneumococcal polysaccharide conjugate vaccines prevent pneumococcal
disease in infants, but their efficacy against pneumococcal community-acquired pneumonia …

Objectives To develop evidence-based European League Against Rheumatism (EULAR)
recommendations for vaccination in patients with autoimmune inflammatory rheumatic …

To determine the burden of community-acquired pneumonia (CAP) affecting adults in North
America, a comprehensive literature review was conducted to examine the incidence …

We performed a systematic review of the literature to establish conclusive evidence of risk
factors for community-acquired pneumonia (CAP). Observational studies (cross-sectional …

Although it varies with age and geographical distribution, the global burden of infection with
Streptococcus pneumoniae (pneumococcus) remains considerable. The elderly, and …

Streptococcus pneumoniae is a major pathogen causing pneumonia with over 2 million
deaths annually, especially in young children and the elderly. To date, at least 98 different …

Invasive disease from Streptococcus pneumoniae (pneumococcus) is a major cause of
illness and death in the United States, with an estimated 43,500 cases and 5,000 deaths …

Background The serotype-specific effectiveness of 23-valent pneumococcal polysaccharide
vaccine (PPV23) against pneumococcal pneumonia has not been established in people …